The probiotic [i]Propionibacteriumfreudenreichii[/i] as a new adjuvant for TRAIL-based therapy in colorectal cancer - Archive ouverte HAL Access content directly
Poster Communications Year : 2016

The probiotic [i]Propionibacteriumfreudenreichii[/i] as a new adjuvant for TRAIL-based therapy in colorectal cancer


TNF-Related Apoptosis-Inducing Ligand (TRAIL) is a well-known apoptosis inducer, which activates the extrinsic death pathway. TRAIL is pro-apoptotic on colon cancer cells, while not cytotoxic towards normal healthy cells. However, its clinical use is limited by cell resistance to cell death which occurs in approximately 50% of cancer cells. Short Chain Fatty Acids (SCFA) are also known to specifically induce apoptosis of cancer cells. In accordance, we have shown that food grade dairy propionibacteria induce intrinsic apoptosis of colon cancer cells, via the production and release of SCFA (propionate and acetate) acting on mitochondria. Here, we investigated possible synergistic effect between Propionibacterium freudenreichii and TRAIL. Indeed, we hypothesized that acting on both extrinsic and intrinsic death pathways may exert a synergistic pro-apoptotic effect. Whole transcriptomic analysis demonstrated that propionibacterial supernatant or propionibacterial metabolites (propionate and acetate), in combination with TRAIL, increased pro-apoptotic gene expression (TRAIL-R2/DR5) and decreased anti-apoptotic gene expression (FLIP, XIAP) in HT29 human colon cancer cells. The revealed synergistic pro-apoptotic effect, depending on both death receptors (TRAIL-R1/DR4, TRAIL-R2/DR5) and caspases (caspase-8, -9 and -3) activation, was lethal on cancer cells but not on normal human intestinal epithelial cells (HIEC), and was inhibited by Bcl-2 expression. Finally, milk fermented by P. freudenreichii induced HT29 cells apoptosis and enhanced TRAIL cytotoxic activity, as did P. freudenreichii DMEM culture supernatants or its SCFA metabolites. These results open new perspectives for food grade P. freudenreichii-containing products in order to potentiate TRAIL-based cancer therapy in colorectal cancer.
No file

Dates and versions

hal-01372131 , version 1 (26-09-2016)


  • HAL Id : hal-01372131 , version 1
  • PRODINRA : 371605


Fabien Cousin, Sandrine Jouan-Lanhouet, Nathalie Théret, Catherine Brenner, Elodie Jouan, et al.. The probiotic [i]Propionibacteriumfreudenreichii[/i] as a new adjuvant for TRAIL-based therapy in colorectal cancer. 4 International Symposium on Propionibacteria and Bibfidobacteria, Sep 2016, Cork, Ireland. , 2016. ⟨hal-01372131⟩
534 View
0 Download


Gmail Facebook X LinkedIn More